- Home
- JBTM vs TFX Comparison
JBTM vs TFX Comparison
Compare JBTM & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JBTM
- TFX
- Stock Information
- Founded
- JBTM 1994
- TFX 1943
- Country
- JBTM United States
- TFX United States
- Employees
- JBTM N/A
- TFX N/A
- Industry
- JBTM
- TFX Medical/Dental Instruments
- Sector
- JBTM
- TFX Health Care
- Exchange
- JBTM Nasdaq
- TFX Nasdaq
- Market Cap
- JBTM 6.4B
- TFX 6.0B
- IPO Year
- JBTM N/A
- TFX N/A
- Fundamental
- Price
- JBTM $94.27
- TFX $129.48
- Analyst Decision
- JBTM Strong Buy
- TFX Hold
- Analyst Count
- JBTM 1
- TFX 10
- Target Price
- JBTM $143.00
- TFX $192.75
- AVG Volume (30 Days)
- JBTM 631.7K
- TFX 1.6M
- Earning Date
- JBTM 04-30-2025
- TFX 05-01-2025
- Dividend Yield
- JBTM 0.21%
- TFX 1.05%
- EPS Growth
- JBTM N/A
- TFX N/A
- EPS
- JBTM 2.65
- TFX 1.48
- Revenue
- JBTM $1,716,000,000.00
- TFX $3,047,324,000.00
- Revenue This Year
- JBTM $113.87
- TFX $1.40
- Revenue Next Year
- JBTM $4.58
- TFX $4.85
- P/E Ratio
- JBTM $35.84
- TFX $86.90
- Revenue Growth
- JBTM 3.10
- TFX 2.45
- 52 Week Low
- JBTM $82.64
- TFX $124.66
- 52 Week High
- JBTM $139.05
- TFX $249.91
- Technical
- Relative Strength Index (RSI)
- JBTM N/A
- TFX 38.95
- Support Level
- JBTM N/A
- TFX $126.36
- Resistance Level
- JBTM N/A
- TFX $132.51
- Average True Range (ATR)
- JBTM 0.00
- TFX 5.10
- MACD
- JBTM 0.00
- TFX 0.19
- Stochastic Oscillator
- JBTM 0.00
- TFX 27.94
About JBTM JBT Marel Corporation
JBT Marel Corp is a technology solutions provider to segments of the food and beverage industry. It designs, produces, and services products and systems for a broad range of end markets, generating roughly one-half of annual revenue from recurring parts, services, rebuilds, and leasing operations.
About TFX Teleflex Incorporated
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2023 sales), interventional (17%), anesthesia (13%), surgical (14%), interventional urology (11%), original-equipment manufacturing (11%), and other (10%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.